Pharmacy Times articleshttps://www.pharmacytimes.com/newsPharmacy Times articles© 2026 MJH Life Sciences™ and Pharmacy Times. All rights reserved.Sat, 27 Jun 2026 19:47:28 +00005en-us14447https://www.pharmacytimes.com/newshttps://www.pharmacytimes.com/logo.webphttps://www.pharmacytimes.com/view/the-biosimilar-conversation-nobody-is-having-at-the-pharmacy-counter-why-adoption-is-still-struggling-and-what-we-can-do-about-ithttps://www.pharmacytimes.com/view/the-biosimilar-conversation-nobody-is-having-at-the-pharmacy-counter-why-adoption-is-still-struggling-and-what-we-can-do-about-it<![CDATA[Biosimilars are equally safe and cut costs. Pharmacists can ease patient fears at the counter.]]>Fri, 26 Jun 2026 19:09:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/fda-accepts-nda-for-giredestrant-in-early-stage-er-positive-breast-cancer-under-priority-reviewhttps://www.pharmacytimes.com/view/fda-accepts-nda-for-giredestrant-in-early-stage-er-positive-breast-cancer-under-priority-review<![CDATA[Priority review NDA puts oral SERD giredestrant on PDUFA track for ER-positive, HER2-negative breast cancer, cutting recurrence risk in lidERA.]]>Fri, 26 Jun 2026 15:52:48 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/high-risk-low-benefit-treatments-for-chronic-low-back-pain-demand-re-evaluationhttps://www.pharmacytimes.com/view/high-risk-low-benefit-treatments-for-chronic-low-back-pain-demand-re-evaluation<![CDATA[In an interview with Pharmacy Times, Caitlin Jones, PhD, discusses why high-risk, low-benefit treatments for chronic low back pain require greater scrutiny.]]>Fri, 26 Jun 2026 15:17:33 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/updated-2025-2026-covid-19-vaccine-nearly-halved-ed-visits-hospitalizations-in-cdc-funded-studyhttps://www.pharmacytimes.com/view/updated-2025-2026-covid-19-vaccine-nearly-halved-ed-visits-hospitalizations-in-cdc-funded-study<![CDATA[Interim data—briefly held back from the CDC’s own weekly report—show the reformulated shot added meaningful protection even among adults with substantial existing immunity.]]>Fri, 26 Jun 2026 15:10:44 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/centanafadine-demonstrates-statistically-significant-clinically-relevant-improvements-in-adhd-symptomshttps://www.pharmacytimes.com/view/centanafadine-demonstrates-statistically-significant-clinically-relevant-improvements-in-adhd-symptoms<![CDATA[Compared with placebo, adult patients with ADHD and comorbid anxiety had greater change from baseline in AISRS total score at week 8.]]>Fri, 26 Jun 2026 15:00:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/what-criteria-identify-a-crswnp-patient-as-a-biologic-candidate-https://www.pharmacytimes.com/view/what-criteria-identify-a-crswnp-patient-as-a-biologic-candidate-<![CDATA[Timothy Clifford, PharmD, outlines how quality-of-life impact, comorbid conditions, and prior therapy failures guide biologic selection for CRSwNP. ]]>Fri, 26 Jun 2026 13:45:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/otc-naloxone-expands-access-but-cost-and-distribution-gaps-still-limit-overdose-preventionhttps://www.pharmacytimes.com/view/otc-naloxone-expands-access-but-cost-and-distribution-gaps-still-limit-overdose-prevention<![CDATA[In an interview with Pharmacy Times, Alison Newman, MPH, program operations specialist with the Center for Community-Engaged Drug Education, Epidemiology, and Research at the Addictions, Drug &amp; Alcohol Institute at the University of Washington, discusses the significance of OTC naloxone availability and the barriers that remain despite the introduction of additional products.]]>Fri, 26 Jun 2026 13:34:10 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/csu-management-from-antihistamine-escalation-to-targeted-biologic-therapyhttps://www.pharmacytimes.com/view/csu-management-from-antihistamine-escalation-to-targeted-biologic-therapy<![CDATA[Aderonke Adeboye, PharmD, discusses the clinical red flags that signal a patient with CSU needs advanced therapy and how specialty pharmacists guide treatment selection and support long-term adherence for biologics and emerging oral agents.]]>Fri, 26 Jun 2026 13:30:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/listening-first-how-to-start-guide-and-personalize-menopause-conversations-with-patienthttps://www.pharmacytimes.com/view/listening-first-how-to-start-guide-and-personalize-menopause-conversations-with-patient<![CDATA[Learn how new nonhormonal menopause drugs ease hot flashes, improve sleep, and who benefits—plus key side effects and liver monitoring.]]>Fri, 26 Jun 2026 12:05:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/from-trial-data-to-real-world-practice-safety-monitoring-and-patient-selection-for-vms-treatmenthttps://www.pharmacytimes.com/view/from-trial-data-to-real-world-practice-safety-monitoring-and-patient-selection-for-vms-treatment<![CDATA[Phase 3 SKYLIGHT and OASIS trials show rapid relief of menopausal hot flashes—often within one week—plus strong safety data, with sleep outcomes under close study.]]>Fri, 26 Jun 2026 12:00:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/cenrifki-becomes-first-eu-approved-therapy-targeting-disability-progression-in-nonrelapsing-spmshttps://www.pharmacytimes.com/view/cenrifki-becomes-first-eu-approved-therapy-targeting-disability-progression-in-nonrelapsing-spms<![CDATA[The European Commission approved tolebrutinib as the first therapy targeting disability progression in adults with nonrelapsing secondary progressive multiple sclerosis (SPMS).]]>Thu, 25 Jun 2026 20:01:22 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/beyond-injections-the-rise-of-oral-glp-1-therapyhttps://www.pharmacytimes.com/view/beyond-injections-the-rise-of-oral-glp-1-therapy<![CDATA[Oral semaglutide delivers significant weight loss in OASIS trials, offering needle-free obesity therapy.]]>Thu, 25 Jun 2026 18:49:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/applying-astct-infectious-disease-guidelines-a-pharmacist-perspective-on-cmv-hhv-6-and-fungal-prophylaxishttps://www.pharmacytimes.com/view/applying-astct-infectious-disease-guidelines-a-pharmacist-perspective-on-cmv-hhv-6-and-fungal-prophylaxis<![CDATA[Updated ASTCT infectious disease guidelines reshape approaches to prophylaxis, treatment thresholds, and drug-drug interactions in opportunistic infections.]]>Thu, 25 Jun 2026 17:01:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/glp-1-reimbursement-crisis-what-independent-pharmacies-need-to-know-about-staying-viablehttps://www.pharmacytimes.com/view/glp-1-reimbursement-crisis-what-independent-pharmacies-need-to-know-about-staying-viable<![CDATA[GoodRx's David Graziano breaks down how fluctuating acquisition costs, narrow formularies, and retrospective reimbursement adjustments are squeezing independent pharmacies—and what solutions exist to help them remain competitive.]]>Thu, 25 Jun 2026 16:09:08 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/automation-in-pharmacy-strategies-for-health-system-successhttps://www.pharmacytimes.com/view/automation-in-pharmacy-strategies-for-health-system-success<![CDATA[Evaluating, implementing, and optimizing automation technologies that improve safety, efficiency, and patient care outcomes are practical strategies for health-system pharmacy leaders.]]>Thu, 25 Jun 2026 16:00:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/beyond-triple-therapy-how-pharmacists-can-identify-copd-patients-who-need-a-biologichttps://www.pharmacytimes.com/view/beyond-triple-therapy-how-pharmacists-can-identify-copd-patients-who-need-a-biologic<![CDATA[Monica Dougherty, PharmD, BCACP, explains how the 2026 GOLD guideline updates use blood eosinophil counts to guide biologic therapy decisions for patients with COPD.]]>Thu, 25 Jun 2026 15:32:24 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/chronic-low-back-pain-recognizing-treatment-harm-and-improving-access-to-better-carehttps://www.pharmacytimes.com/view/chronic-low-back-pain-recognizing-treatment-harm-and-improving-access-to-better-care<![CDATA[Pharmacy Times speaks with Caitlin Jones, PHD, on how evidence gaps, opioid dependence, and misaligned incentives can undermine pain care.]]>Thu, 25 Jun 2026 15:21:03 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/faqs-amid-the-ongoing-us-measles-outbreakshttps://www.pharmacytimes.com/view/faqs-amid-the-ongoing-us-measles-outbreaks<![CDATA[This FAQ outlines current measles cases, key drivers of increasing cases, and the essential role pharmacists play in vaccination, patient counseling, case recognition, and combating vaccine misinformation.]]>Thu, 25 Jun 2026 13:30:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/putting-the-2026-ckm-guidelines-into-practice-a-pharmacist-s-perspectivehttps://www.pharmacytimes.com/view/putting-the-2026-ckm-guidelines-into-practice-a-pharmacist-s-perspective<![CDATA[Lavinia Salama, PharmD, joins Craig Beavers, PharmD, to discuss implementing the 2026 CKM guidelines in clinical practice.]]>Wed, 24 Jun 2026 20:59:26 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/fda-approves-sacituzumab-govitecan-for-first-line-treatment-of-advanced-triple-negative-breast-cancerhttps://www.pharmacytimes.com/view/fda-approves-sacituzumab-govitecan-for-first-line-treatment-of-advanced-triple-negative-breast-cancer<![CDATA[Supported by improved progression-free survival outcomes in the phase 3 ASCENT-03 and ASCENT-04/KEYNOTE-D19 trials, sacituzumab govitecan-hziy received FDA approval as both a monotherapy and combination therapy with pembrolizumab.]]>Wed, 24 Jun 2026 19:46:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/medicare-is-finally-covering-glp-1s-for-weight-loss-what-the-bridge-program-means-for-your-practicehttps://www.pharmacytimes.com/view/medicare-is-finally-covering-glp-1s-for-weight-loss-what-the-bridge-program-means-for-your-practice<![CDATA[Pharmacists who understand the workflow before July 1 will be the ones patients and prescribers depend on when the program launches.]]>Wed, 24 Jun 2026 18:23:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/fda-grants-fast-track-designation-to-vs-7375-for-kras-g12d-mutated-advanced-nsclchttps://www.pharmacytimes.com/view/fda-grants-fast-track-designation-to-vs-7375-for-kras-g12d-mutated-advanced-nsclc<![CDATA[The FDA grants fast track designation to VS-7375, an oral KRAS G12D dual ON/OFF inhibitor, advancing new hope for pretreated non–small cell lung cancer (NSCLC).]]>Wed, 24 Jun 2026 18:16:55 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/mckesson-ideashare-2026-why-independent-pharmacies-must-expand-clinical-services-now-according-to-health-mart-s-suzanne-feeneyhttps://www.pharmacytimes.com/view/mckesson-ideashare-2026-why-independent-pharmacies-must-expand-clinical-services-now-according-to-health-mart-s-suzanne-feeney<![CDATA[Suzanne Feeney, PharmD, explains why expanding clinical services—from immunizations to chronic disease management—is a critical growth strategy for independent pharmacies navigating reimbursement pressures and shifting legislation.]]>Wed, 24 Jun 2026 17:56:55 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/olezarsen-receives-fda-approval-to-reduce-triglycerides-risk-of-acute-pancreatitis-in-severe-hypertriglyceridemiahttps://www.pharmacytimes.com/view/olezarsen-receives-fda-approval-to-reduce-triglycerides-risk-of-acute-pancreatitis-in-severe-hypertriglyceridemia<![CDATA[The agent is to be used alongside diet adjustments in adult patients.]]>Wed, 24 Jun 2026 17:55:57 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/fda-approves-palbociclib-based-maintenance-regimen-for-hr-positive-her2-positive-metastatic-breast-cancerhttps://www.pharmacytimes.com/view/fda-approves-palbociclib-based-maintenance-regimen-for-hr-positive-her2-positive-metastatic-breast-cancer<![CDATA[The FDA approved palbociclib-based maintenance therapy for HR-positive, HER2-positive advanced breast cancer following a significant progression-free survival benefit in PATINA.]]>Wed, 24 Jun 2026 17:53:32 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/ada-2026-diabetes-technology-innovations-expand-beyond-traditional-cgm-usehttps://www.pharmacytimes.com/view/ada-2026-diabetes-technology-innovations-expand-beyond-traditional-cgm-use<![CDATA[As these tools continue to move into mainstream diabetes management, it is increasingly important that pharmacists have proficiency.]]>Wed, 24 Jun 2026 16:00:00 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/who-should-carry-naloxone-addressing-common-misconceptions-about-overdose-preventionhttps://www.pharmacytimes.com/view/who-should-carry-naloxone-addressing-common-misconceptions-about-overdose-prevention<![CDATA[Pharmacy Times interviews Alison Newman, MPH, Program Operations Specialist at CEDEER, about who should carry naloxone, common misconceptions surrounding overdose reversal and fentanyl-related overdoses, and the broader strategies needed to reduce overdose deaths.]]>Wed, 24 Jun 2026 15:35:24 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/fda-expands-otc-naloxone-access-what-it-means-for-patients-and-pharmacistshttps://www.pharmacytimes.com/view/fda-expands-otc-naloxone-access-what-it-means-for-patients-and-pharmacists<![CDATA[Pharmacy Times interviews Alison Newman, MPH, Program Operations Specialist at CEDEER, about the FDA's expansion of over-the-counter naloxone access, remaining barriers to availability, and the critical role pharmacists play in overdose prevention and patient education.]]>Wed, 24 Jun 2026 14:34:25 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/fda-narrows-compounding-rules-for-glp-1s-how-pharmacists-should-respondhttps://www.pharmacytimes.com/view/fda-narrows-compounding-rules-for-glp-1s-how-pharmacists-should-respond<![CDATA[A compliance expert breaks down the FDA's move to exclude glucagon-like peptide-1 (GLP-1) drugs from the 503B bulk's list and what it means for pharmacists and patients.]]>Wed, 24 Jun 2026 14:06:52 GMTPharmacy TimesusPharmacy Times Articleshttps://www.pharmacytimes.com/view/mckesson-ideashare-2026-why-pharmacist-advocacy-matters-according-to-trailblazer-award-winner-shahida-choudhryhttps://www.pharmacytimes.com/view/mckesson-ideashare-2026-why-pharmacist-advocacy-matters-according-to-trailblazer-award-winner-shahida-choudhry<![CDATA[Shahida Choudhry, PharmD, discusses earning McKesson ideaShare's inaugural Trailblazer Award, building an integrated primary care and pharmacy model, and using advocacy and social media to elevate independent pharmacy.]]>Wed, 24 Jun 2026 13:42:33 GMTPharmacy TimesusPharmacy Times Articles